Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Weill Medical College of Cornell University
With
Forest Laboratories
Patients with multiple sclerosis who are experiencing mood lability and symptoms of depression will be randomized to receive either escitalopram 10mg/day or placebo tablets for a period of 6 weeks. It is hypothesized that patients receiving medication will experience a greater normalization of their emotional instability and a greater reduction in their depressive symptoms at the end of the six-week trial than those who are not receiving medication.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Clinical diagnosis of multiple sclerosis
Having mild to moderate depressive symptoms, with or without emotional lability
Experiencing psychological distress
You may not be if
Meeting DSM-IV diagnostic criteria for Major Depressive Disorder or another Axis 1 diagnosis
Cognitive impairment
The presence of an unstable medical illness that might preclude completion of the study -
